The disease-causing tau V337M mutation induces tau hypophosphorylation and perturbs axon morphology pathways

Abstract

Tau aggregation is a hallmark of several neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. There are disease-causing variants of the tau-encoding gene,MAPT, and the presence of tau aggregates is highly correlated with disease progression. However, the molecular mechanisms linking pathological tau to neuronal dysfunction are not well understood due to our incomplete understanding of the normal functions of tau in development and aging and how these processes change in the context of causal disease variants of tau. To address these questions in an unbiased manner, we conducted multi-omic characterization of iPSC-derived neurons harboring theMAPTV337M mutation. RNA-seq and phosphoproteomics revealed that both V337M tau and tau knockdown consistently perturbed levels of transcripts and phosphorylation of proteins related to axonogenesis or axon morphology. Surprisingly, we found that neurons with V337M tau had much lower tau phosphorylation than neurons with WT tau. We conducted functional genomics screens to uncover regulators of tau phosphorylation in neurons and found that factors involved in axonogenesis modified tau phosphorylation in bothMAPTWT andMAPTV337M neurons. Intriguingly, the p38 MAPK pathway specifically modified tau phosphorylation inMAPTV337M neurons. We propose that V337M tau might perturb axon morphology pathways and tau hypophosphorylation via a “loss of function” mechanism, which could contribute to previously reported cognitive changes in preclinicalMAPTgene carriers.